Ophthalmology and Eye Disease Research at ARNAS Garibaldi Di Catania

The Department of Ophthalmology is actively studying a range of eye diseases, with a strong focus on thyroid eye disease and postoperative inflammation after cataract surgery. These trials are designed to improve symptom control, reduce inflammation, and evaluate new treatment options that may offer better outcomes for patients with vision-threatening conditions.

  • Thyroid Eye Disease and related eye-symptom relief
  • Post-cataract surgery inflammation and recovery
  • Testing new therapies to improve comfort, safety, and eye health

Research at this site also reflects broader interest in analytical, diagnostic, and therapeutic techniques for ophthalmic care, supporting more precise and effective treatment strategies.

Oncology Research in Gastrointestinal Cancers

A major part of the clinical trial portfolio at ARNAS Garibaldi Di Catania focuses on neoplasms, especially cancers of the colon, rectum, stomach, and gastroesophageal junction. These studies are evaluating newer cancer treatments, combination strategies, and biomarker-guided approaches to improve survival and disease control.

  • Metastatic colorectal cancer and locally advanced rectal cancer
  • Gastric and gastroesophageal junction cancer
  • Testing treatment effectiveness and personalized therapy choices

The research includes efforts to refine treatment for patients with advanced disease, including studies aimed at better response rates, longer survival, and improved matching of therapy to tumor biology.

Breast, Gynecologic, and Other Solid Tumor Studies

The site is also involved in trials for several other cancer types, including breast cancer, ovarian cancer, fallopian tube cancer, and peritoneal neoplasms. These studies are generally focused on improving outcomes after standard treatment, reducing recurrence risk, and testing targeted or immune-based therapies in difficult-to-treat cancers.

  • High-risk HER2-positive breast cancer and triple negative breast cancer
  • Ovarian, fallopian tube, and peritoneal cancers
  • Evaluating new treatment options to delay relapse and improve disease-free survival

This area of research highlights a broad commitment to modern oncology, including studies that aim to make treatment more effective after surgery or initial therapy.

Hematology and Immune System Trials

Clinical research at the site includes hemic and lymphatic diseases as well as immune system diseases, with studies in mantle cell lymphoma, follicular lymphoma, chronic immune thrombocytopenia, and sickle cell disease. These trials are assessing new ways to improve blood counts, control disease activity, and support longer-term management.

  • Lymphoma and relapsed or refractory blood cancers
  • Chronic immune thrombocytopenia
  • Testing therapies that may improve disease control and reduce complications

The research reflects an emphasis on both treatment effectiveness and safety in conditions where long-term disease management is especially important.

Cardiometabolic and Metabolic Disease Research

Another important area of activity involves cardiovascular diseases and nutritional and metabolic diseases, including atherosclerotic cardiovascular disease, type 2 diabetes, hypertension, overweight, obesity, and MASH/NASH. These studies are exploring prevention and treatment approaches that may lower long-term risk and improve overall health.

  • Cardiovascular disease prevention and risk reduction
  • Type 2 diabetes, hypertension, and weight management
  • Evaluating therapies to improve metabolic control and reduce major complications

The cardiometabolic portfolio shows a strong interest in preventing serious events while also addressing common chronic conditions that affect quality of life.

Respiratory, Genetic, and Precision Medicine Studies

The research program also includes respiratory tract diseases and congenital, hereditary, and neonatal conditions, with trials in non-small cell lung cancer and mutation-defined cancers such as KRAS, HER2, and FGFR2b related disease. These studies are aimed at improving treatment selection and testing targeted therapies for patients with specific biological features.

  • Advanced non-small cell lung cancer
  • Biomarker-selected cancers such as KRAS– and HER2-driven disease
  • Using precision medicine to match treatment with tumor characteristics

This work highlights the site’s interest in more personalized care, where treatment decisions are guided by tumor markers and disease biology.